viewGenprex, Inc.

Genprex gets generic name approval for non-small cell lung cancer drug

The United States Adopted Names Council signed off on the name quaratusugene ozeplasmid for what the company calls GPX-001

quaratusugene ozeplasmid on a 'hello my name is' tag
Genprex is currently seeking proprietary approval for the brand name GPX-001

Genprex Inc (NASDAQ:GNPX) announced Thursday that the United States Adopted Names (USAN) Council approved the generic name quaratusugene ozeplasmid, the company’s non-small cell lung cancer drug formerly known as Oncoprex.

The USAN Council is the agency tasked with selecting simple, unique nonproprietary names for drug candidates. Genprex is also seeking proprietary approval for the brand name GPX-001. Obtaining both approvals is a necessary step in obtaining marketing approval.

“The USAN’s adoption of our non-proprietary name is another step toward advancing our lead drug candidate, GPX-001 for non-small cell lung cancer, toward commercialization,” CEO Rodney Varner said in a statement. “We look forward to the adoption and rollout of a brand name for this drug as we continue to move along the development pathway.”

READ: Genprex ramps up production of active agent for its lung cancer drug Oncoprex

To preserve the Oncoprex brand, Genprex has renamed its proprietar, non-viral nanoparticle delivery system the Oncoprex Nanoparticle Delivery Platform, which is used to deliver its oncology platform technologies.

“In the meantime, we’ve focused our branding efforts on our proprietary, non-viral nanoparticle delivery system with our recognized Oncoprex name,” Varner added. “We believe this delivery system is a significant differentiator for GPX-001, as well as an important platform delivery system that could be used for additional drug candidates.”

Genprex, based in Austin, Texas, is also developing GPX-002, a gene therapy drug candidate for diabetes.

Contact Andrew Kessel at [email protected]

Follow him on Twitter @andrew_kessel

Quick facts: Genprex, Inc.

Price: 3.8 USD

Market: NASDAQ
Market Cap: $147.71 m


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Genprex, Inc. named herein, including the promotion by the Company of Genprex, Inc. in any Content on the Site, the Company receives from said...



Genprex Inc making progress on branding for its lead cancer therapy, Oncoprex

Genprex Inc (NASDAQ:GNPX) CEO Rodney Varner tells Proactive the biotech has initiated the first phase of branding for its lead drug candidate, Oncoprex, an immunogene therapy to treat non-small cell lung cancer. Varner says the Texas-based company has completed the creation and submission of...

on 6/8/19

2 min read